Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

IKT

+ Watchlist+ Portfolio

Inhibikase Therapeutics, Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.38
52-Week Range
$1.36 – $2.61
Market Cap
$193.57M
P/E (TTM)
—
EPS (TTM)
-0.40
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.47
PEG Ratio
—
Return on Equity
-52.87%
Return on Assets
-33.76%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
15.34
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-24.46M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$83.84M

Market Snapshot

About

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing protein kinase inhibitors to modify the course of Parkinson's disease and related neurodegenerative disorders. The company's lead product candidate, IkT-148009, is designed to inhibit c-Abl, a protein kinase that has been implicated in the progression of Parkinson's disease by promoting the accumulation of toxic protein aggregates. Inhibikase is conducting clinical trials to evaluate IkT-148009's potential to slow or stop disease progression rather than just treating symptoms. The company represents a novel approach to addressing neurodegenerative diseases by targeting underlying disease mechanisms at the molecular level.